Biotech Values

[genisi]

LLY drug Solanezumab shows some signs of efficacy.

Guess that's why unlike the open-label extension study of bapineuzumab that was halted, for solanezumab:

An ongoing, open-label extension study, EXPEDITION-EXT, is fully enrolled and would continue as planned.